Introduction
============

Immunoglobulin A nephropathy (IgAN) is a type of immune complex-mediated glomerulonephritis that is pathologically characterized by the deposition of IgA immune complexes in the mesangium of the kidney ([@b1-etm-11-01-49]). IgAN is the most common form of primary glomerulonephritis worldwide, particularly in China ([@b2-etm-11-01-49]). In addition, 15--20% of patients with IgAN develop end-stage renal failure (ESRD) within 10 years, and 30--40% within 20 years ([@b3-etm-11-01-49]--[@b5-etm-11-01-49]). Proteinuria is regarded as the most severe risk factor for unfavorable renal prognosis, and its reduction is an important therapeutic goal in clinical practice ([@b6-etm-11-01-49]).

Optimized supportive therapy is the key strategy for patients with IgAN who are at risk of progression, with renin-angiotensin-system (RAS) inhibitors being the most common treatment. However, the optimal immunosuppressive treatment strategy for patients with IgAN suffering from moderate to severe proteinuria remains uncertain. According to the guidelines outlined by the clinical practice guideline for glomerulonephritis ([@b7-etm-11-01-49]), patients with IgAN who suffer from persistent proteinuria of \>1 g/day following 6 months of treatment with RAS inhibitors are recommended to undergo corticosteroid therapy. There is an ongoing debate over the efficacy and safety of immunosuppressive agents other than glucocorticoid monotherapy in patients with IgAN who present with moderate to severe proteinuria; specifically, the use of relatively novel agents, including leflunomide (LET) and mycophenolate mofetil (MMF).

Increasing attention has been paid to the role of immunosuppressive agents in the treatment of patients with IgAN. The present report aimed to generate a meta-analysis from the most up-to-date studies regarding the safety and efficacy of various immunosuppressive therapeutic strategies for the treatment of patients with IgAN, in order to provide comprehensive current information to nephrologists to aid decision making. China has the largest population worldwide, and has a high incidence of IgAN. In order to exclude interferences that may be due to the ethnicity of patients, the present meta-analysis was performed using studies involving Chinese patients exclusively.

Methods
=======

### Information sources and search strategy

All randomized controlled trials (RCTs) that assessed the efficacy and safety of various immunosuppressive agents in the treatment of Chinese patients with IgAN between 1990 and September 2013 were included in the present meta-analysis. Numerous databases were searched for eligible RCTs, including: PubMed, Excerpta Medica database, the Cochrane Library, Chinese National Knowledge Infrastructure, Wanfang, Weipu, Chinese Biomedical Literature Database and Qinghuatongfang. The following medical terms and phrases were used for the search: 'Immunoglobulin A nephropathy'; 'IgA nephropathy'; 'Berger disease'; 'glomerulonephritis'; 'RCT'; 'controlled clinical trial' and 'immunosuppressive therapy'. Only RCTs published in either English or Chinese were considered to be eligible. The title and abstract of the search results were analyzed by two independent investigators. According to the inclusion criteria, reference lists from all identified articles were also searched.

### Inclusion criteria

The following inclusion criteria were used in the present meta-analysis: (i) Prospective RCTs comparing various immunosuppressive agents; (ii) the selected patients with IgAN were Chinese, whether adults or children; (iii) diagnosis of IgAN was performed via renal biopsy; and (iv) the study was published in English or Chinese.

### Exclusion criteria

Studies were excluded if they: (i) Assessed secondary types of IgAN or patients who were not Chinese; (ii) were designed without randomization, such as retrospective studies and descriptive studies; (iii) included the use of traditional Chinese medicine, with its unknown additional effects on immunosuppressive agents and uncertain doses of active components; (iv) only assessed corticosteroids; or (v) failed to exclude patients with other systemic diseases, such as lupus, Henoch-Schonlein purpura and rheumatoid arthritis.

### Study selection

All of the studies included in the present meta-analysis were independently assessed by two reviewers, in accordance with the set criteria, through retrieved abstracts and, if necessary the full texts. Disagreements were resolved in consultation with a third reviewer until a consensus was reached.

### Data extraction

Data were independently extracted from each study by two reviewers using a predesigned review form (Microsoft Office Excel 2010; Microsoft Corporation, Redmond, WA, USA); disagreements were resolved in discussion with a third reviewer until a consensus was reached.

The review form included the following data: First author and unit of each study; year of publication; country of publication; journal; patient characteristics, including age, gender and ethnicity; interventions, including type of immunosuppressive agents, dose and usage; and the methodology of the RCTs. Baseline, final proteinuria, serum creatinine and serum albumin levels, and the type of outcome (complete remission, partial remission and total effective rate) were recorded. In addition, the presence of side effects, including: Elevated levels of liver enzymes; hypertension; diabetes; glaucoma; cataracts; leukocytopenia and infection, were recorded.

### Assessments of methodological quality

The respective qualities of the RCTs were independently assessed by two authors, using the scoring system developed by Jadad *et al* ([@b8-etm-11-01-49]). The quality scoring system was as follows: (i) Generation of random sequences (2=appropriate, computer generated random numbers or similar methods; 1=unknown, randomized trials but did not describe the method of random distribution; 0=inappropriate, adopted the method of alternate distribution such as single and double); (ii) randomization concealment (2=appropriate, clinicians and patients matched by unpredictable assigned sequence method; 1=unknown, only stating the use of a random number table or other random allocation scheme; 0=description not clear); (iii) blinding method (2=appropriate, using the identical placebo or similar methods; 1=not clear, statement for blinding method, but no description available; 0=inappropriate, did not adopt the method of double blinding, or inappropriate blinding such as tablets and injections); (iv) withdrawal (1=described the withdrawal or exit and indicated the reasons; 0=did not describe the withdrawal or exit or the reasons thereof).

### Data analysis and statistical methods

Statistical analyses were performed using Review Manager software (version 5.0.2; The Cochrane Collaboration, Oxford, UK). Two-sided P-values were obtained via the χ^2^ test and P\<0.05 was considered to indicate a statistically significant difference. Dichotomous outcome data were analyzed using the odds ratio, 95% confidence intervals (CI), and the standardized mean difference (SMD). 95% CI was used as a summary estimator for continuous outcomes. The heterogeneity of the trial results was investigated visually by examination of the plots and statistically via the heterogeneity I^2^ values. In order to reveal possible publication bias, funnel plots of study size vs. effect size were visually assessed for the total clinical remission rate.

Results
=======

### Study characteristics

The combined search identified 1,747 articles, of which 1,653 were excluded during the initial review. The main reasons for the exclusion of eligible RCTs were: Non-randomization, evaluation of other interventions (e.g. non-immunosuppressive agents), and a lack of renal outcomes of interest. Furthermore, animal and basic research studies were excluded, in addition to a number of review articles on the topic. The full-text versions of the remaining 94 articles were analyzed and a further 64 articles were excluded for similar reasons. Overall, 29 studies ([@b9-etm-11-01-49]--[@b37-etm-11-01-49]), including 1,466 patients, were included in the present meta-analysis ([Fig. 1](#f1-etm-11-01-49){ref-type="fig"}). The following comparisons were analyzed: MMF (or plus steroid) vs. steroid therapy alone (n=6); azathioprine (AZA) (or plus steroid) vs. steroid (n=5); LET (or plus steroid) vs. CTX (or plus steroid) (n=4); CTX (or plus steroid) vs. steroid (n=2). In 13 studies, LET was involved in the comparison. The characteristics of the included RCTs are shown in [Table I](#tI-etm-11-01-49){ref-type="table"}.

Effects of interventions
------------------------

### AZA (or plus steroid) vs. steroid

Five RCTs ([@b9-etm-11-01-49]--[@b13-etm-11-01-49]) involving 292 patients compared the administration of AZA (or plus steroids) with steroid therapy. AZA (2--5 mg/kg/day) was administered for 6--24 months. Prednisolone (0.8--1.0 mg/kg/day) was administered for 4--8 weeks and subsequently tapered off within one year ([@b9-etm-11-01-49]--[@b13-etm-11-01-49]). Patients receiving AZA demonstrated significantly increased complete response (CR)/partial response (CR) proteinuria remission rates \[CR/PR; relative risk (RR), 3.43; 95% confidence interval (CI), 1.92--6.12, P\<0.0001\] ([Fig. 2](#f2-etm-11-01-49){ref-type="fig"}), as compared with the steroid therapy alone.

### MMF (or plus steroid) vs. steroid

Six RCTs ([@b14-etm-11-01-49]--[@b19-etm-11-01-49]) involving 253 patients compared MMF (or plus steroid) with steroid therapy alone. MMF (1.0--2.0 g/day) was orally administered for 3--6 months, and gradually tapered thereafter. The immunosuppressive treatment lasted for \<12 months ([@b14-etm-11-01-49]--[@b19-etm-11-01-49]). Patients receiving MMF demonstrated significantly increased CR/PR proteinuria remission rates (CR/PR; RR, 2.19; 95% CI, 1.25--3.85, P=0.006) ([Fig. 3](#f3-etm-11-01-49){ref-type="fig"}), as compared with the steroid therapy alone.

### LET (or plus steroid) vs. steroid

A total of 13 RCTs ([@b20-etm-11-01-49]--[@b32-etm-11-01-49]) involving 623 patients compared LET (or plus steroid) with steroid therapy alone. LET (50 mg/day) was orally administered for 3 days, reduced to 20--30 mg/day for 3 months, and subsequently tapered ([@b20-etm-11-01-49]--[@b32-etm-11-01-49]). LET demonstrated a marked advantage on CR/PR proteinuria remission, as compared with the steroid therapy (CR/PR; RR, 2.64; 95% CI, 1.80--3.86; P\<0.00001) ([Fig. 4](#f4-etm-11-01-49){ref-type="fig"}).

### CTX (or plus steroid) vs. steroid

Two RCTs ([@b19-etm-11-01-49],[@b33-etm-11-01-49]) involving 72 patients compared CTX (or plus steroid) treatment with steroid therapy alone. CTX (0.5--0.75 g/m^2^) was intravenously administered in monthly pulses for six months, followed by quarterly pulses for the next six months. The immunosuppressive therapy lasted for 12 months in total ([@b19-etm-11-01-49]--[@b33-etm-11-01-49]). Patients receiving CTX (or plus steroid) demonstrated markedly increased reductions in urinary protein excretion levels by the end of treatment, as compared with patients treated with steroid therapy exclusively (SMD, 0.91; 95% CI, 0.41--1.41; P=0.0004) ([Fig. 5](#f5-etm-11-01-49){ref-type="fig"}).

### LET (or plus steroid) vs. CTX (or plus steroid)

Four RCTs ([@b34-etm-11-01-49]--[@b37-etm-11-01-49]) involving 226 patients compared LET (or plus steroid) with CTX (or plus steroid). LET (50 mg/day) was orally administered for 3 days, tapered, and subsequently reduced to 20 mg/day for 3 months ([@b34-etm-11-01-49]--[@b37-etm-11-01-49]). LET was significantly more effective in inducing remission, as compared with CTX (CR/PR; RR, 2.01; 95% CI, 1.08--3.75; P=0.03) ([Fig. 6](#f6-etm-11-01-49){ref-type="fig"}).

### Side effects

Although it is challenging to statistically analyze the side effects in a single comparison, the major side effects for each agent were recorded. A total of 143 patients were treated with AZA, and adverse events were reported in 79 patients, including: Myelosuppression (n=5; 6.3%), liver dysfunction (n=6; 7.6%), and digestive symptoms (n=8; 0.12%). Infection was the most frequent side effect of AZA (14/79, 17.7%). A total of 16 patients (14.8%) treated with MMF demonstrated digestive symptoms; whereas a further 4 patients (3.7%) exhibited elevated liver enzymes. A total of 13/267 patients (4.7%) treated with LET demonstrated elevated liver enzymes, and a further 10 patients (3.7%) exhibited digestive symptoms.

No obvious nephrotoxicity directly related to the administration of immunosuppressive agents was demonstrated. In the 'LET (or plus steroid) vs. CTX (or plus steroid)' comparison, 9 and 13 patients treated with LET and CTX, respectively, demonstrated liver dysfunction; whereas 1 and 3 patients receiving CTX and LET, respectively, demonstrated digestive symptoms. Furthermore, leukocytopenia was detected in 6 patients treated with CTX, whereas 5 individuals treated with LET demonstrated alopecia.

### Publication bias and sensitivity analysis

Publication bias was examined using funnel plots, which did not show any significant visual asymmetry ([Fig. 7](#f7-etm-11-01-49){ref-type="fig"}). Furthermore, in order to assess the robustness of the meta-analysis results, a sensitivity analysis focusing on the patients and the quality of the RCTs was conducted. Analysis was performed by excluding low quality RCTs. As outlined in [Table I](#tI-etm-11-01-49){ref-type="table"}, the quality scores of all included RCTs were not high; therefore, any RCTs scoring less than 3 points were excluded (n=7). This sensitivity analysis did not substantially change the results of the comparisons.

Discussion
==========

IgAN, which was initially identified by Berger and Hinglais in 1968 ([@b1-etm-11-01-49]), is the most common form of primary glomerular nephritis in Asia. The immunological mechanisms associated with the development and progression of IgAN suggest that immunosuppressive therapies may have a beneficial role in the treatment of IgAN and associated proteinuria. Although previous studies have demonstrated that the administration of glucocorticoids may reduce the risk of ESRD in patients with IgAN ([@b38-etm-11-01-49],[@b39-etm-11-01-49]), the optimal immunosuppressive treatment strategy for patients with IgAN who suffer with moderate to severe proteinuria remains uncertain. In the present meta-analysis, a comprehensive literature search with limited restrictions in publication language was performed in order to compare the efficacy and safety of immunosuppressive agents such as CTX, LET, MMF and AZA, which are widely used in the treatment of Chinese patients with IgAN.

A total of 1,466 patients from 29 studies ([@b9-etm-11-01-49]--[@b37-etm-11-01-49]) were included in the present meta-analysis. As too few studies reported long-term outcomes, the present meta-analysis only reviewed short-term parameters in order to evaluate the efficacy of the respective treatments, including the final urinary protein excretion and therapeutic remission (complete or partial) of the participants. The most frequently used definition for 'partial remission' of proteinuria was 0.3--2.0 g/day or a decrease of 50%. Complete remission of proteinuria was defined as \<0.3 g/day and serum albumin \>35 g/l with normal renal function. However, these definitions may be heterogeneous.

Notably, the patients demonstrated an improved treatment response to AZA administration, as compared with steroid treatment alone (RR, 3.43; 95% CI; 1.92--6.12; P\<0.0001). In addition, following treatment with MMF therapy, the Chinese patients with IgAN demonstrated significantly increased CR/PR remission rates (CR/PR; RR, 2.19; 95% CI, 1.25--3.85; P=0.006), as compared with the administration of steroid alone. In the analysis of 'LET (or plus steroid) versus steroid', the administration of LET demonstrated an improved response, as compared with steroid treatment alone. Tolerable side effects were demonstrated in patients administered AZA, MMF and LET. Only two studies involving 72 patients compared CTX plus steroid and steroid therapy alone; therefore further high quality RCTs are required in the future to determine the effects of CTX. Four studies were included in the analysis of 'CTX (or plus steroid) versus LET (or plus steroid)'; LET administration was significantly effective in inducing remission of proteinuria and was associated with a lower incidence of adverse reactions, as compared with CTX.

Some findings of the present study were consistent with the results of previous studies in patients of various ethnicities. Several RCTs have demonstrated that, when combined with steroid treatment, CTX was able to reduce urinary protein levels and conserve kidney function in patients with IgAN ([@b19-etm-11-01-49],[@b33-etm-11-01-49]). Yoshikawa *et al* ([@b40-etm-11-01-49]) demonstrated that the administration of AZA plus steroid therapy resulted in the increased complete remission of proteinuria in 80 juvenile patients newly diagnosed with IgAN. However, the efficacy of MMF administration in patients with IgAN differs among ethnicities. In a Belgian study that assessed MMF vs. placebo in 34 patients, Maes *et al* ([@b41-etm-11-01-49]) demonstrated an average proteinuria level of 1.8 g/day; whereas no differences in the reduction of proteinuria or preservation of glomerular filtration rate were demonstrated. Similarly, in a North American study, Frisch *et al* ([@b42-etm-11-01-49]) demonstrated that a 1-year regimen of MMF vs. placebo in patients with IgAN with an initial average proteinuria level of 2.7 g/day provided no benefits over 24 months. The efficacy and safety of LET in the treatment of patients with IgAN in other ethnicities is unknown, and no relevant RCTs were found. Due to the heterogeneity of the results from previous studies, the optimal immunosuppressive therapeutic strategy for the treatment of patients with IgAN remains controversial. The reasons for this heterogeneity require further investigation, however, the following may be considered contributing factors: Ethnicity differences; variations in the levels of therapeutic agent achieved; limited number of trials and small sample sizes; and suboptimal methodological quality. The results of the present meta-analysis demonstrated the potential of immunosuppressive agents, including AZA, CTX, MMF and LET, as a short-term (6--12 months) therapeutic strategy for the treatment of proteinuria in patients with IgAN.

The present meta-analysis had various strengths. Firstly, in an attempt to minimize bias, rigorous methods were used and only randomized trials were included. Secondly, as compared with previous meta-analyses, a greater number of studies were included and attempts were made to tabulate the occurrence of adverse events. It remains premature to recommend the routine use of AZA, CTX, MMF and LET immunosuppressive agents as treatment for patients with IgAN, for various reasons. The data analyzed in the present meta-analysis were obtained from short-term studies with small sample sizes, which were generally conducted in a single center. Furthermore, as the analysis was conducted on pooled data from published papers, individual patient and original data were not available, which prevented a more detailed analysis from being completed, which may have yielded more comprehensive results.

In conclusion, based on the Chinese patients and short duration RCTs examined, the administration of AZA, MMF, LET and CTX, demonstrated superior potency in inducing the remission of proteinuria in patients with IgAN with tolerable adverse effects, as compared with steroid treatment. In addition, as compared with CTX, LET administration demonstrated a lower incidence of adverse reactions. Furthermore, the results of the present meta-analysis support the need for a large, high-quality multicenter trial in order to ascertain whether immunosuppressive treatments may be effective in a broad population of patients with high-risk IgAN, specifically to determine their effects in kidney failure.
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Note added at revision of article
=================================

Subsequently to the publication of the above article, an interested reader drew to our attention that the article described the use of the drug acetazolamide for IgA nephropathy on a number of occasions in the text, whereas the references refer to the drug azathioprine. The authors confirmed that, owing to an oversight on their part, all the references to "acetazolamide" in their paper (abbreviated as 'AZA') should have been written as "azathioprine". Given the nature of this error, note that the drug name for 'AZA' has been corrected in the article itself, and this is a revised version of the original article.
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![Reductions in the excretion of urinary protein in randomized controlled trials comparing CTX (or plus steroid) treatment and steroid treatment alone in patients with immunoglobulin A nephropathy. CTX, cyclophosphamide; SD, standard deviation; IV, inverse variance; CI, confidence interval.](ETM-11-01-49-g04){#f5-etm-11-01-49}

![Complete/partial remission proteinuria rates in randomized controlled trials comparing LET (or plus steroid) and CTX (or plus steroid) treatment in patients with immunoglobulin A nephropathy. LET, leflunomide; CTX, cyclophosphamide; OR, odds ratio; CI, confidence interval.](ETM-11-01-49-g05){#f6-etm-11-01-49}
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###### 

Characteristics of the included trials.

  Study (reference)                                 Number of patients   Mean age (years)                                           Length (months)   Baseline proteinuria (g/day)   Initial dose of immunosuppressive agents (per day)     Quality grade
  ------------------------------------------------- -------------------- ---------------------------------------------------------- ----------------- ------------------------------ ------------------------------------------------------ ---------------
  AZA (or plus steroid) vs. steroid                                                                                                                                                                                                         
    Huang S ([@b9-etm-11-01-49])                    36                   30.8/30.8                                                  9                 1.78±1.11/1.82±1.23            2 mg/kg AZA                                            3
    Kuang B ([@b10-etm-11-01-49])                   64                   18.0--68.0^[a](#tfn2-etm-11-01-49){ref-type="table-fn"}^   6                 0.39±0.09/0.38±0.09            2 mg/kg AZA                                            1
    Li YN ([@b11-etm-11-01-49])                     42                   18.0--65.0^[a](#tfn2-etm-11-01-49){ref-type="table-fn"}^   12                1.41±1.29/1.32±0.91            1.5 mg/kg AZA                                          3
    Ma FL ([@b12-etm-11-01-49])                     80                   37.1/37.5                                                  NC                1.80±1.17/1.83±1.52            2 mg/kg AZA                                            2
    Xu H ([@b13-etm-11-01-49])                      70                   38.4/35.2                                                  18                38.42±12.80/35.26±13.27        2 mg/kg AZA                                            4
  MMF (or plus steroid) vs. steroid                                                                                                                                                                                                         
    Tang SC ([@b18-etm-11-01-49])                   40                   42.1/43.3                                                  8                 1.80±0.21/1.87±0.28            2 g (weight, ≥60kg) or 1.5 g (weight, \<60kg) MMF      3
    Chen XM ([@b14-etm-11-01-49])                   62                   28.0/29.0                                                  24                3.20±1.70/2.90±1.50            1.0 g (weight. \<50kg) or 1.5 g (weight, \>50kg) MMF   2
    Chen XSh ([@b15-etm-11-01-49])                  39                   42.7/38.6                                                  12                NC                             1.5 g MMF                                              3
    Guo QY ([@b16-etm-11-01-49])                    34                   8.7/9.4                                                    12                0.97±0.34/1.13±0.23            800--1000 mg/m^2^ MMF                                  2
    Huang Z ([@b17-etm-11-01-49])                   38                   34.0/32.0                                                  2                 6.71±5.53/5.89±4.90            0.5--2 gMMF                                            2
    Wang WM ([@b19-etm-11-01-49])                   40                   40.0/39.4                                                  12                1.75±1.60/1.51±0.92            1.0--1.5 g MMF (weight, \<50kg is 1.0g)                3
  LET (or plus steroid) vs. steroid                                                                                                                                                                                                         
    Lou TQ ([@b25-etm-11-01-49])                    55                   33.0/33.0                                                  6                 1.30±0.70/1.60±0.80            60 mg LET                                              4
    Yang FY ([@b30-etm-11-01-49])                   82                   36.6/38.2                                                  6                 2.60±1.40/2.50±1.20            50 mg LET                                              4
    Hu RH ([@b22-etm-11-01-49])                     45                   42.7/42.7                                                  9                 2.16±0.64/2.08±0.73            50 mg LET                                              3
    Zhang Y ([@b32-etm-11-01-49])                   42                   16--68^[a](#tfn2-etm-11-01-49){ref-type="table-fn"}^       6                 2.85±0.80/NC                   50 mg LET                                              3
    Wang L ([@b29-etm-11-01-49])                    36                   36.3/34.2                                                  6                 2.38±1.31/2.42±1.28            50 mg LET                                              2
    Fu Q ([@b21-etm-11-01-49])                      37                   32.6/36.5                                                  1                 2.56±0.90/2.48±0.82            50 mg LET                                              3
    Li T ([@b24-etm-11-01-49])                      60                   36.4/37.7                                                  6                 2.40±1.30/2.50±1.40            50 mg LET                                              2
    Cao LO ([@b20-etm-11-01-49])                    36                   40.0/38.0                                                  6                 2.4(1.4--4.0)/2.6(1.7--3.1)    40 mg LET                                              3
    Huang YX ([@b23-etm-11-01-49])                  62                   43.5/43.5                                                  6                 2.30±1.30/2.20±1.20            40 mg LET                                              4
    Pu L ([@b26-etm-11-01-49])                      60                   36.2/37.4                                                  6                 2.10±0.94/2.08±1.03            20 mg LET                                              3
    Zhang LW ([@b31-etm-11-01-49])                  30                   43.5/42.8                                                  6                 2.43±1.32/2.24±1.14            50 mg LET                                              3
    Sun MD ([@b28-etm-11-01-49])                    36                   37.0/37.0                                                  3                 2.68 ±0.68/2.66±0.69           50 mg LET                                              3
    Shen P ([@b27-etm-11-01-49])                    42                   32.5/31.4                                                  6                 3.16±1.42/3.08±1.52            50 mg LET                                              3
  CTX (or plus steroid) vs. steroid                                                                                                                                                                                                         
    Wang WM ([@b19-etm-11-01-49])                   40                   39.5/39.4                                                  12                1.74±1.06/1.51±0.92            0.5--0.75 g/m^2^ CTX                                   3
    Liu Y ([@b33-etm-11-01-49])                     32                   NC                                                         12                1.55±0.44/1.38±0.62            8--12 mg/kg CTX                                        3
  LET (or plus steroid) vs. CTX (or plus steroid)                                                                                                                                                                                           
    Guo M ([@b34-etm-11-01-49])                     60                   NC                                                         28                5.12±1.08/5.14±1.34            50 mg LET; 8--12 mg/kg CTX                             3
    Zhong ShH ([@b37-etm-11-01-49])                 56                   NC                                                         7                 5.16±1.32/5.10±1.07            50 mg LET; 8--12 mg/kg CTX                             3
    Zhang HF ([@b36-etm-11-01-49])                  40                   43.7/43.7                                                  4                 NC                             50 mg LET; 8--12 mg/kg CTX                             4
    Sun ZhX ([@b35-etm-11-01-49])                   70                   35.7/35.7                                                  12                2.61±1.38/2.54±1.28            50 mg LET; 0.75 g/m^2^ CTX                             3

AZA, azathioprine; MMF, mycophenolatemofetil; LET, leflunomide; CTX, cyclophosphamide; NC, not clear.

Age range.
